Biocept Raises $2.2 Million from Ally Bridge; Plans China Expansion

Biocept , a San Diego liquid biopsy company, raised $2.2 million from Hong Kong's Ally Bridge LB Healthcare Master Fund in a private placement. Biocept provides physicians with personal medicine tests for cancer treatment, using its Target Selector™ platform to analyze circulating tumor cells and circulating tumor DNA. In addition to the capital, Ally Bridge will help Biocept develop a strategic plan to bring its liquid biopsy platform to China. More details.... Stock Symbol: (NSDQ: BIOC) Share this with colleagues: // //